PubRank

Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers

Clinical Trial ID NCT02683863

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02683863

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 10.26
2 Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012 7.58
3 Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012 6.51
4 Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005 5.29
5 The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009 3.84
6 Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011 3.38
7 The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal 2009 2.49
8 Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012 2.32
9 Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 2012 2.22
10 Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011 1.81
11 Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One 2011 1.10
12 New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep 2007 1.01
13 Disease-modifying treatments for progressive multiple sclerosis. Mult Scler 2013 0.94
Next 100